source
- MapLight shifts focus to schizophrenia drug after mixed Phase 2 results, raises $150 millionMapLight Therapeutics reported mixed outcomes from its Phase 2 Zephyr trial of the muscarinic agonist ML-007C-MA. A twice‑daily dose achieved the study’s primary endpoint with notable reductions in…
- FTC launches antitrust probe into Epic Systems over alleged anticompetitive practicesFederal Trade Commission investigators have reached out to at least three people as part of a broad inquiry into Epic Systems' business practices. Epic, the nation's largest electronic health reco…